Maastricht 2017 Meeting Highlights Registration Programme Overview Exhibition Virtual Exhibition Hotels Satellite Meetings Visa Letter Application Star Alliance Travel Discount

10 - 12 February 2017, MECC Maastricht,The Netherlands.

This Meeting has been awarded 15 CME credits.

Advanced Descemet's membrane endothelial keratoplasty (DMEK) for complex endothelial disorders

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Session Details

Session Title: Cornea
Session Date/Time: Friday 10/02/2017 | 08:30-10:00
Paper Time: 09:36
Venue: Brussels Room 0.4

First Author: R.Quilendrino THE NETHERLANDS
Co Author(s): I. Dapena  L. Baydoun  G. Melles           

Abstract Details


To describe advanced Descemet membrane endothelial keratoplasty (DMEK) and its technical modifications to standardized モno ᆳtouchヤ DMEK for handling complex, endothelial disorders.


Netherlands Institute for Innovative Ocular Surgery / Tertiary referral center


Complex DMEK cases (severe, long standing corneal edema; previously failed penetrating keratoplasty (PK) or endothelial keratoplasty (EK) grafts; eyes at risk for hypotony; eyes with large iris defects, after vitrectomy; eyes with a glaucoma drainage device (GDD) tube and/or anterior chamber intraocular lens (ACᆳIOL); phakic eyes; and/or eyes with a shallow AC), were included in this study. Modifications of the DMEK-technique were evaluated by intraoperative video recordings and anterior segment optical coherence tomography images.


Failed PK grafts required a modified descemetorhexis, sizing and positioning of the DMEK-graft. Removal of a failed EK graft was more difficult than a descemetorhexis in primary DMEK. Pressurization and air-fluid exchange was modified in case of excessive corneal edema and/or hypotony. A specific air bubble maneuver was utilized to lift a DMEK-graft in the presence of a GDD tube. An angle-supported AC-IOL should be removed, whereas stable iris-fixated AC-IOLs may be left in-situ.


Advanced DMEK may include technical adjustments to facilitate managing complex endothelial disorders.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented

Back to previous